acyl-CoA dehydrogenase family member 8Genealiases: ACAD-8 · ARC42 · IBDH
Q-omics provides the consensus-scored ACAD8 profile across patient tissues and cancer cell-line models. ACAD8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ACAD8 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, ACAD8 RNA expression shows 20,267 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, and ACC as cancer lineages where ACAD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACAD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACAD8 survival associations across molecular data types. ACAD8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACAD8 RNA expression–survival associations across cancer types. High ACAD8 expression shows favorable associations in KIRP, READ, LUAD, KIRC, HNSC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ACAD8 RNA expression.
This table summarizes ACAD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACAD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACAD8 shows lower tumor expression in KIRP, KIRC, COAD, HNSC and THCA and higher tumor expression in LUAD. The KIRP box plot shows higher ACAD8 RNA expression in normal versus tumor tissue (log2 FC = −1.376, t-test p < 0.001).
This table shows molecular features associated with ACAD8 in patient tissues and cancer cell lines. In patient samples, ACAD8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACAD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
